Ex-CV Sales Rep Drops Ranexa Marketing Suit

Law360, New York (December 17, 2010, 7:02 PM EST) -- A former CV Therapeutics Inc. sales representative has dropped his False Claims Act suit accusing the company of endangering heart patients through off-label marketing of its angina drug Ranexa following the federal government's refusal to intervene in the case.

Plaintiff Ricardo Forges cited only the government’s decision not to intervene in his one-paragraph notice of voluntary dismissal filed Thursday in the U.S. District Court for the Northern District of California.

According to Forges’ October 2008 complaint against CV, the U.S. Food and Drug Administration only approved...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.